{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:07:02Z","timestamp":1790802422345,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117010","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:49:10Z","timestamp":1788068950000},"page":"117010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean-Yves","family":"Blay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lamure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-2882","authenticated-orcid":false,"given":"Waisse","family":"Waissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Sunyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chassagne-Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-4830","authenticated-orcid":false,"given":"Amine","family":"Belhabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-4137","authenticated-orcid":false,"given":"Yann","family":"Guillermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sebban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117010_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Prim"},{"issue":"23","key":"10.1016\/j.ejca.2026.117010_bib2","first-page":"05074","article-title":"Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"S0923-7534","author":"Ferreri","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/WNL.40.1.80","article-title":"Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy","volume":"40","author":"DeAngelis","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.ejca.2026.117010_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.1998.16.3.864","article-title":"High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series","volume":"16","author":"Blay","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115068","article-title":"Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies","volume":"213","author":"de Groot","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117010_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib8","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V86.8.2922.2922","article-title":"The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression","volume":"86","author":"Blay","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117010_bib9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/neuonc\/noaf221","article-title":"Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma","volume":"28","author":"Omuro","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib11","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2026.117010_bib12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long- term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2026.117010_bib13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib14","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib15","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2026.117010_bib16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/neuonc\/noad224","article-title":"Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: final results of the HOVON 105\/ALLG NHL 24 study","volume":"26","author":"Bromberg","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hon.2666","article-title":"Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis","volume":"37","author":"Schmitt","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib18","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/cancers13081920","article-title":"The role of rituximab in the treatment of primary central nervous system lymphoma","volume":"13","author":"Van Dijck","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.117010_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/annonc\/mdp529","article-title":"Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d\u2032Etude des Lymphomes de l\u2032Adulte (GELA)","volume":"21","author":"Ghesqui\u00e8res","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib21","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/ijerph21020189","article-title":"Consore: a powerful federated data mining tool driving a french research network to accelerate cancer research","volume":"21","author":"Gu\u00e9rin","year":"2024","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"10.1016\/j.ejca.2026.117010_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000415","article-title":"From data strategy to implementation to advance cancer research and cancer care: a French comprehensive cancer center experience","volume":"2","author":"Heudel","year":"2023","journal-title":"PLOS Digit Health"},{"issue":"1","key":"10.1016\/j.ejca.2026.117010_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/11.suppl_1.S39","article-title":"Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French F\u00e9d\u00e9ration Nationale des Centres de Lutte contre le Cancer","volume":"11","author":"Blay","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117010_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.10.036","article-title":"Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse","volume":"72","author":"Fossard","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117010_bib26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s10147-021-01963-3","article-title":"Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer center","volume":"26","author":"Heudel","year":"2021","journal-title":"Int J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:39Z","timestamp":1790800419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0959804926007914"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117010"}}